Sligo biotech developing a synthetic antimicrobial compound to combat drug-resistant pathogens.
| Date | Round | Amount |
|---|---|---|
| May 2021 | Seed Sligo biotech Nektr Technologies raised €1m, half from the Western Development Commission, with Enterprise Ireland, to bring its antimicrobial compound to market. | $1.1M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.